Press Release: Ossianix : Ossianix Expands and Extends Its Research Collaboration with Lundbeck on CNS Therapeutics

PHILADELPHIA--(BUSINESS WIRE)--Ossianix, Inc. today announced an expansion and extension of its strategic research collaboration with H. Lundbeck A/S (Lundbeck). This collaboration follows a previous equity investment in 2012 and prior research collaboration in 2013. The collaboration will use Ossianix's innovative single domain antibody platform based on the shark VNAR structure to deliver next generation CNS biotherapeutics. Ossianix's has developed a novel Blood Brain Barrier (BBB) targeting